增强KCC2功能的作用降低了间活动,并防止叶发作
Florian Donneger1, Adrien Zanin1, Jeremy Besson1
1Institut du Fer à Moulin, Inserm, Sorbonne Université, UMR-S 1270, Paris 75005, France.
概括
两种化合物,即普罗克佩拉 (PCPZ) 和CLP-257,增强了KCC2的功能,以恢复化物平衡. 这些KCC2增强剂在模型中有效降低了发作,显示了对抗药性半径叶 (mTLE) 的治疗潜力.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- K/Cl 共运输体KCC2对于神经元化物梯度和GABAergic信号传递效率至关重要.
- 功能障碍的KCC2通过导致脱极化GABA信号和病态神经元活动,导致发作.
- 通过KCC2增强恢复化物平衡是一种神经系统疾病的潜在治疗策略.
研究的目的:
- 为了研究通过什么机制甲 (PCPZ) 和CLP-257增强KCC2功能.
- 评估PCPZ和CLP-257在临床前模型中的抗发作作用.
- 提供证据证明KCC2增强剂在耐药性半径叶 (mTLE) 的治疗潜力.
主要方法:
- 在用PCPZ和CLP-257治疗的皮质神经元中评估了KCC2功能,聚类和膜扩散.
- 测量GABAA受体介导电流,以确定CLP-257对突触和突触外电流的影响.
- 利用人类mTLE脑组织的体外记录和小鼠模型的体内记录来测试抗发作功效.
主要成果:
- 无论是PCPZ还是CLP-257,都提高了KCC2的功能,并在皮层神经元中集群,而不会改变酸化.
- CLP-257可以选择性地增加外突触GABAA受体电流.
- PCPZ和CLP-257 (或其前药CLP-290) 在人类mTLE组织和小鼠模型中显著抑制了自发性型活动.
结论:
- 证实PCPZ和CLP-257是KCC2增强剂,可以调节神经元化物平衡.
- 这些化合物在相关模型中显示出显著的抗发作作用.
- 增强KCC2的化合物代表了耐药mTLE的有希望的治疗途径.
相关概念视频
Epilepsy and Seizures: Overview
1.8K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.8K
Seizures: Classification
2.5K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.5K
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.8K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.8K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
Antiepileptic Drugs: Potassium Channel Activators
1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Seizures l: Introduction
43
Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
43


